BladderBoneBrainBreastCervicalColonEsophagealKidneyLaryngealLeukemia CancerLiverLungLymphomaMouthOvarianPancreaticProstateRectalSkinTesticularThroatUterineOBGYN & Women's HealthHematology & OncologyPathologyBladder CancerBone CancerBrain CancerBreast CancerCervical CancerColon CancerEsophageal CancerKidney CancerLaryngeal CancerLeukemiaLiver CancerLung CancerLymphoma CancerMouth CancerOvarian CancerPancreatic CancerProstate CancerRectal CancerSkin CancerTesticular CancerThroat CancerUterine CancerCancerChemotherapyHealth TechnologyGenetics
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
MONDAY, Sept. 28, 2015 (HealthDay News) -- A 21-gene risk of recurrence score can identify patients with breast cancer who may be spared chemotherapy, according to a study published online Sept. 28 in the New England Journal of Medicine to coincide with the 2015 European Cancer Congress, held from Sept. 25 to 29 in Vienna.
Joseph A. Sparano, M.D., from the Montefiore Medical Center in Bronx, N.Y., and colleagues conducted a prospective trial involving 10,253 women with hormone-receptor-positive, human epidermal growth factor receptor type 2 (HER2)-negative, axillary node-negative breast cancer. A reverse transcriptase-polymerase chain reaction assay of 21 genes was performed on tumor tissue and the results were used to calculate a score indicating the risk of recurrence. Patients with a recurrence score of 0 to 10 (low risk of recurrence) were assigned to receive endocrine therapy without chemotherapy.
The researchers found that 15.9 percent of participants had a recurrence score of 0 to 10 and received endocrine therapy without chemotherapy. In this patient population, the rates of invasive disease-free survival, freedom from recurrence from breast cancer at a distant site, freedom from recurrence of breast cancer at a distant or local-regional site, and overall survival were 93.8, 99.3, 98.7, and 98.0 percent, respectively, at five years.
"This prospective study involving uniformly treated patients with hormone-receptor positive, HER2-negative, axillary node-negative breast cancer supports the clinical validity of the 21-gene assay in identifying patients who may be safely spared adjuvant chemotherapy," the authors write.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at firstname.lastname@example.org with any questions.
Updated on May 31, 2022
Read this Next
Other Trending Articles